Engineering precision oncology: Targeting tumors and immune cells with lentiviral vectors - PubMed
3 hours ago
- #Lentiviral Vectors
- #Precision Oncology
- #Gene Therapy
- Lentiviral vectors (LVs) are versatile for stable gene delivery but VSV-G-pseudotyped LVs have broad tropism and serum sensitivity limiting in vivo use.
- Advances in LV pseudotyping include natural viral envelopes (e.g., measles, baboon endogenous retrovirus) and engineered strategies like receptor-binding domains for targeted transduction.
- Next-generation innovations involve displaying cytokines or antibody fragments, and VSV-G mutants to enhance specificity for immune and tumor cells.
- Engineered virus-like particles (VLPs) enable in vivo delivery of CRISPR-Cas9 and gene-editing complexes for precision oncology.
- Targeted LVs and VLPs support selective in vivo CAR T/NK cell generation, tumor modification, and cell-restricted gene editing.